Residency · Residency · Psychiatry

Bipolar I Disorder: Acute Mania and Maintenance Treatment

Diagnosis of Bipolar I Disorder

DSM-5-TR Criteria for Manic Episode

A distinct period of abnormally and persistently elevated, expansive, or irritable mood AND increased goal-directed activity or energy, lasting at least 7 days (or any duration if hospitalization is required) During the mood disturbance, three or more of the following (four if mood is only irritable): Inflated self-esteem or grandiosity. Decreased need for sleep (feels rested after 3 hours) More talkative than usual or pressured speech. Flight of ideas or racing thoughts. Distractibility. Increase in goal-directed activity or psychomotor agitation. Excessive involvement in activities with high potential for painful consequences (spending sprees, sexual indiscretions, foolish investments) Mnemonic: DIG FAST (Distractibility, Impulsivity/Indiscretion, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, Talkativeness) Marked functional impairment, hospitalization, or psychotic features. Not attributable to substance use or another medical condition. Bipolar I requires only ONE manic episode -- depressive episodes are common but not required for diagnosis.

Distinguishing Mania from Other Conditions

Substance-induced mania: stimulants (cocaine, methamphetamine), corticosteroids, anabolic steroids; temporal relationship with substance use; may persist beyond expected pharmacologic duration. Hyperthyroidism: thyroid function tests in first-episode mania. ADHD: chronic course, onset in childhood, no episodic pattern, no decreased need for sleep. Schizoaffective disorder: psychotic symptoms persist beyond mood episodes. Borderline personality disorder: mood shifts are rapid (hours, not days/weeks), reactive to interpersonal events, no decreased need for sleep or grandiosity.

Mixed Features Specifier

Full manic episode with >=3 depressive symptoms simultaneously. Associated with higher suicide risk, longer episodes, more frequent recurrence, poorer treatment response. Valproate and atypical antipsychotics may be preferred over lithium for mixed episodes.

Acute Management of Mania

Pharmacotherapy for Acute Mania

First-line options:. Lithium monotherapy (effect size moderate; classic agent; 1-2 week onset) Valproate monotherapy (rapid loading possible; broader spectrum for mixed states) Atypical antipsychotics: aripiprazole, quetiapine, risperidone, olanzapine, cariprazine, asenapine (fastest onset of antimanic effect, often within days) Combination therapy (lithium or valproate + atypical antipsychotic): superior to monotherapy for severe mania. Second-line: carbamazepine, haloperidol, ziprasidone. Adjunctive benzodiazepines: lorazepam or clonazepam for acute agitation, insomnia; taper as mood stabilizer takes effect.

Lithium in Acute Mania

Target serum level: 0.8-1.2 mEq/L for acute mania (higher than maintenance) Loading strategies: start 600-900 mg/day in divided doses; titrate based on levels drawn 12 hours post-dose. Response typically within 7-14 days. Monitor: renal function, thyroid function, calcium, ECG (in patients >40 or with cardiac risk factors)

Valproate in Acute Mania

Oral loading: 20-30 mg/kg/day achieves therapeutic levels within 1-2 days. Target level: 80-120 mcg/mL. Rapid antimanic effect, particularly effective for mixed features. Monitor: LFTs, CBC (thrombocytopenia), ammonia if encephalopathy suspected.

Antipsychotics in Acute Mania

Atypical antipsychotics provide the fastest antimanic effect. Olanzapine IM for acute agitation in the emergency setting. Quetiapine effective for both manic and depressive poles (useful for maintenance) Aripiprazole: partial dopamine agonism; lower metabolic burden; available as LAI.

Discontinuation of Antidepressants

If patient is on an antidepressant when mania occurs, it should be tapered and discontinued. Antidepressant monotherapy is contraindicated in bipolar I -- can trigger or worsen mania, accelerate cycling.

Maintenance Treatment

Maintenance Agents: Comparative Summary

Goals

Prevent recurrence of both manic and depressive episodes. Minimize interepisode symptoms and functional impairment. Reduce suicide risk (lithium has unique antisuicidal properties) Manage comorbidities (substance use, anxiety, metabolic syndrome)

Lithium for Maintenance

The most extensively studied maintenance agent. Target serum level: 0.6-0.8 mEq/L for maintenance (lower than acute) Unique antisuicidal effect: meta-analyses consistently show lithium reduces suicide risk by 60-80% in bipolar disorder. Effective for preventing manic episodes; moderate efficacy for preventing depressive episodes. Long-term adverse effects: nephrogenic diabetes insipidus (polyuria, polydipsia), hypothyroidism (20-30%), chronic kidney disease (monitor eGFR), hyperparathyroidism/hypercalcemia, weight gain. Narrow therapeutic index; toxicity at >1.5 mEq/L (tremor, ataxia, confusion, seizures, renal failure)

Valproate for Maintenance

Effective for preventing manic episodes; less evidence for depressive prevention. Target level: 50-100 mcg/mL for maintenance. Preferred for rapid cycling and mixed features. Long-term concerns: weight gain, hepatotoxicity, pancreatitis, teratogenicity, PCOS-like syndrome in women.

Lamotrigine for Maintenance

Primary efficacy is in preventing depressive episodes (not manic) Often used in combination with lithium or an atypical antipsychotic for full-spectrum prophylaxis. Requires slow titration (risk of Stevens-Johnson syndrome): 25 mg/day for 2 weeks, then 50 mg for 2 weeks, then titrate up to 200-400 mg. Titration must be even slower if combined with valproate (which inhibits lamotrigine metabolism)

Atypical Antipsychotics for Maintenance

Quetiapine, aripiprazole, and olanzapine have evidence for maintenance monotherapy. Quetiapine effective for both poles; often combined with lithium or valproate. Long-term metabolic monitoring essential (weight, glucose, lipids) -- especially with olanzapine.

Combination Strategies

Most patients with severe bipolar I disorder will require combination therapy. Common combinations: lithium + lamotrigine (complementary pole coverage), lithium + quetiapine, lithium/valproate + atypical antipsychotic.

<image> A treatment algorithm for acute mania showing severity-based pathways. Start with "Manic episode confirmed." Branch into mild-moderate (oral monotherapy: lithium, valproate, or atypical antipsychotic) and severe/psychotic (combination lithium or valproate + antipsychotic, consider ECT). Show adjunctive benzodiazepine track for agitation/insomnia. Include monitoring requirements for each agent (lithium levels, valproate levels, metabolic monitoring). Second section shows maintenance transition with dose adjustment targets. Clean clinical algorithm with color-coded drug classes. </image>

<image> A comparative efficacy diagram for bipolar maintenance medications showing coverage across the two poles. Use a horizontal spectrum with "Manic Prevention" on the left and "Depressive Prevention" on the right. Place medications along this spectrum based on their relative efficacy: lithium (left-center), valproate (left), lamotrigine (right), quetiapine (center), olanzapine (left-center), aripiprazole (left). Include a vertical axis for antisuicidal effect (lithium highest). Color-coded circles with size proportional to strength of evidence. </image>

<image> A monitoring timeline for lithium therapy showing required laboratory tests at each phase. Initial workup (renal function, TSH, calcium, ECG, pregnancy test), acute phase monitoring (lithium levels every 5-7 days until stable), maintenance monitoring (lithium level, renal function, TSH every 3-6 months; calcium annually). Include toxicity warning signs at each lithium level range (therapeutic 0.6-1.2, concern 1.2-1.5, toxic >1.5). Visual thermometer-style graphic with clinical correlation. </image>

Clinical Pearls

Bipolar I disorder requires only one manic episode for diagnosis -- a patient presenting with depression who has a remote history of a single manic episode has bipolar I, not MDD. Always ask about prior manic symptoms when evaluating depression, especially in young adults, patients with family history of bipolar disorder, or those with atypical depressive features. Lithium is the only psychiatric medication with demonstrated antisuicidal properties -- this should factor into treatment selection, especially in high-risk patients. Antidepressant monotherapy is contraindicated in bipolar I disorder -- always pair with a mood stabilizer or use mood stabilizers alone. Valproate should be avoided in women of childbearing potential due to teratogenicity and PCOS risk. Lamotrigine does NOT treat acute mania -- its role is in maintenance, specifically preventing depressive episodes. Mixed features (mania + depressive symptoms) predict poorer prognosis and may respond better to valproate or atypical antipsychotics than to lithium.

References

• Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.
• Cipriani A, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
• Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-1682.
• APA Practice Guidelines for the Treatment of Patients with Bipolar Disorder. 2nd ed. 2002 (with 2019 guideline watch).
• Stahl SM. Stahl's Essential Psychopharmacology. 5th ed. Cambridge University Press; 2021.

Read this lecture as Markdown